SCHEMBL1802840

SCHEMBL1802840

CCOC(=O)CCC(=O)N1CCC2(CC1)NCC(=O)N2Cc1ccccc1F

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
POLB P06746 2/20 0.47
KDM4E B2RXH2 2/20 0.47
KMT2A Q03164 3/20 0.43
MAPK1 P28482 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TSHR P16473 3/20 0.39
RIPK1 Q13546 1/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
RAB9A P51151 3/20 0.39
MEN1 O00255 2/20 0.39
NPC1 O15118 2/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
NOTUM Q6P988 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1801224 0.83 RAB9A (0.50) ALDH1A1POLBKDM4EKMT2AMAPK1
SCHEMBL1802807 0.82 RIPK1 (0.41) ALDH1A1POLBKDM4EKMT2ATSHR
SCHEMBL1802160 0.80 ALDH1A1 (0.47) ALDH1A1KDM4EKMT2AMAPK1TSHR
SCHEMBL1798596 0.80 SMN1; SMN2 (0.49) ALDH1A1KDM4EKMT2ANPSR1LMNA
SCHEMBL1800533 0.79 ALDH1A1 (0.47) ALDH1A1POLBKDM4EKMT2ANPSR1
SCHEMBL1802032 0.79 CHRM2 (0.52) ALDH1A1POLBKDM4EKMT2ANPSR1
SCHEMBL1801131 0.78 RIPK1 (0.41) ALDH1A1POLBKDM4EKMT2AMAPK1
SCHEMBL1800853 0.78 ALDH1A1 (0.49) ALDH1A1POLBKDM4EKMT2AMAPK1
SCHEMBL1802555 0.77 USP2 (0.52) ALDH1A1POLBKMT2AMAPK1TSHR
SCHEMBL5156459 0.77 ALDH1A1 (0.48) ALDH1A1KDM4EKMT2ANPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US claimed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP claimed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US disclosed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds SI, SSTR4, SLC10A2 ALDH1A1 2780/4885POLB 2915/4885KDM4E 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.